Back to results
US 2010/0249130 A1Published application
Biaryl compositions and methods for modulating a kinase cascade
AssigneeKinex Pharmaceuticals, LLC
InventorDavid G. Hangauer, JR.
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula IB and methods for modulating one or more components of a kinase cascade using these compounds.
Claims22
A method of treating or preventing cancer, comprising administering a compound according to Formula IB:
- or a salt, solvate, hydrate, or prodrug thereof, wherein:
- T is a bond;
- Xy is CY, N, or N—O;
- Xz is CZ;
- Y is selected from hydrogen, hydroxyl, halogen, lower (C1, C2, C3, C4, C5, or C6) alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, and O-benzyl;
- X, is CR, or N, or N—O;
- Xb is CRb, N, or N—O;
- Xc is CRc or N, or N—O;
- Xd is CRd or N, or N—O;
- Xe is CRe, N, or N—O;
- Ra, Rb, Rc, Rd, Re, R4, R5, and R6 are, independently, hydrogen, hydroxyl, halogen, P, C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, O-benzyl, C1, C2, C3, C4, C5, or C6 alkyl-OH, COOH, COO-lower (C1, C2, C3, C4, C5, or C6) alkyl, SO2H, SO2-lower (C1, C2, C3, C4, C5, or C6) alkyl,
- where W is H, or C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkyl-aryl;
- P is SO3H, OSO3H, OPO3H2, OPO3H2, NH2, NHR19, NHR20R21,
- tetrazole, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-K, O—C(O)-lower (C1, C2, C3, C4, C5, or C6) alkyl-L, NH-lower (C1, C2, C3, C4, C5, or C6) alkyl-M, or O-aryl-Q, further wherein lower alkyl is linear or branched alkyl;
- K is C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- L is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- M is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- Q is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- R19, R20 and R21 are C1, C2, C3, C4, C5, or C6 alkyl or R19 and R20 taken together with the attached nitrogen atom form a five membered ring;
- V is a bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, —O—CH2—, —OCH2CH2— or —OCH2CH2CH2—;
- R12, R13, R14, R15, R16, R17, and R18, are, independently, H or C1, C2, C3, C4, C5, or C6 alkyl;
- Z is (CHR1)n—C(O)—NR2(CHR3)m—Ar, where Ar is a substituted or unsubstituted aryl or nitrogen-containing heteroaryl group, R1, R2, and R3 are independently H or C1, C2, C3, C4, C5, or C6 alkyl;
- and
- n and m are independently 0, 1, or 2,
- to a subject, wherein the cancer is selected from renal, liver, or brain cancer.
22 more elements
A composition comprising tamoxifen and a compound of Formula I:
- or a salt, solvate, hydrate, or prodrug thereof, wherein:
- T is a bond, CR12R13, C(O), O, S, S(O), S(O)2, NR14, C(R15R16)C(R17R18), CH2O, or OCH2;
- Xy is CZ, CY, N, or N—O;
- Xz is CZ, CY, N, or N—O;
- at least one of Xy and Xz is CZ;
- Y is selected from hydrogen, hydroxyl, halogen, lower (C1, C2, C3, C4, C5, or C6) alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, and O-benzyl;
- Xa is CRa or N, or N—O;
- Xb is CRb, N, or N—O;
- Xc is CRc or N, or N—O;
- Xd is CRd or N, or N—O;
- Xe is Cite, N, or N—O;
- Ra, Rb, Rc, Rd, Re, R4, R5, and R6 are, independently, hydrogen, hydroxyl, halogen, P, C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkoxy, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-aryl, O-benzyl, C1, C2, C3, C4, C5, or C6 alkyl-OH, COOH, COO-lower (C1, C2, C3, C4, C5, or C6) alkyl, SO2H, SO2-lower (C1, C2, C3, C4, C5, or C6) alkyl,
- where W is H, or C1, C2, C3, C4, C5, or C6 alkyl, C1, C2, C3, C4, C5, or C6 alkyl-aryl;
- P is SO3H, OSO3H, OPO3H2, OPO3H2, NH2, NHR19, NHR20R21,
- tetrazole, O-lower (C1, C2, C3, C4, C5, or C6) alkyl-K, O—C(O)-lower (C1, C2, C3, C4, C5, or C6) alkyl-L, NH-lower (C1, C2, C3, C4, C5, or C6) alkyl-M, or O-aryl-Q, further wherein lower alkyl is linear or branched alkyl;
- K is C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- L is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- M is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- Q is aryl, heteroaryl, OH, C(O)NH2, COOH, SO3H, OSO3H, PO3H2, OPO3H2, NH2, NHR19, NR19R20, SO2R21, glycoside, lower C1, C2, C3, C4, C5, C6 alkoxy, or
- R19, R20 and R21 are C1, C2, C3, C4, C5, or C6 alkyl or R19 and R20 taken together with the attached nitrogen atom form a five membered ring;
- V is a bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, —O—CH2—, —OCH2CH2— or —OCH2CH2CH2—;
- R12, R13, R14, R15, R16, R17, and R18, are, independently, H or C1, C2, C3, C4, C5, or C6 alkyl;
- Z is (CHR1)nC(O)—NR2(CHR3)m—Ar, where Ar is a substituted or unsubstituted aryl or nitrogen-containing heteroaryl group, R1, R2, and R3 are independently H or C1, C2, C3, C4, C5, or C6 alkyl;
- and
- n and m are independently 0, 1, or 2.
22 more elements
Dependencies are inferred from the claim text.